Trial · NCT05071417
Effect Of Semaglutide In Coronary Atheroma Plaque
NCT05071417, Phase 3, Unknown, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect Of Semaglutide In Coronary Atheroma Plaque. Trials, record NCT05071417. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05071417
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect Of Semaglutide In Coronary Atheroma Plaque
- NCT number
- NCT05071417
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
- Conditions
- Atheroscleroses, Coronary
- Interventions
- Semaglutide
- First posted
- 2021-10-08
- Last updated
- 2021-10-08
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Plaque burden modification assessed by coronary CT and plaque quantification | 18 months | The main objective of this trial is to evaluate the effect of Semaglutide on the burden of coronary atherosclerosis, based on the change in Percent Atheroma Volume (PAV) by quantifying atheroma plaque throughout the coronary tree based on the analysis of CCTA in asymptomatic subjects with T2D in optimized and stable treatment with Semaglutide |
| Secondary | Atheroma volume modification assessed by coronary CT and plaque quantification | 18 months | Evaluate the effect of Semaglutide on the change in normalized total atheroma volume |
| Secondary | Percentage of patients with significant plaque regresion assessed by coronary CT | 10 months | Percentage of patients who demonstrated significant plaque regression |
| Secondary | Changes in composition of artery wall assessed by coronary CT and plaque quantification | 18 months | Effect of Semaglutide on the composition and architecture of the coronary artery wall |
| Secondary | Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) | 18 months | Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) |
| Secondary | Incidence of cardiovascular events | 18 months | Incidence and type of cardiovascular events (cardiovascular death, Acute coronary syndrome and stroke) during treatment with Semaglutide. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05071417
GET https://conductscience.org/api/trials/v1/NCT05071417/registered